A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
Open Access
- 9 March 2021
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (3) , e346
Abstract
Background: Relapsed/refractory (R/R) multiple myeloma (MM) patients and primary plasma cell leukemia (PCL) have an unfavorable prognosis and no effective treatment. This study was designed to assess the safety and preliminary efficacy of a novel anti‐B‐cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell in R/R MM and PCL.Methods: Between February 22, 2017, and June 25, 2018, 28 R/R and two R/R primary PCL patients received a median dose of 11.2 × 106 CAR+ cells/kg. The subjects were refractory to a proteasome inhibitor and/or an immunomodulatory agent. Fludarabine and cyclophosphamide were given as lymphodepletion chemotherapy.Results: Results for these 30 consecutive patients who received an anti‐BCMA CAR T cell infusion are reported. The patients had received a median of four prior lines of therapy. A total of 44 different types of adverse events were recorded, and hematologic toxic effects were the most common events of any grade during treatment. Hematologic toxic effects were also the most common events of grade 3 or higher. A total of 29 patients (96.7%) had cytokine release syndrome, which was of grade 1 or 2 in 24 patients (80%) and grade 3 in five patients (16.7%). Neurologic toxic effects only occurred in one patient (3.3%) and were of grade 1. The objective response rate was 90%, and the complete response rate was 43.3%. With a median follow‐up of 12.6 months, the median progression‐free survival (PFS) and overall survival were 5.2 months and 14.0 months. One of the two primary PCL achieved a complete response with a PFS of 307 days. The other patients achieved a very good partial response with a PFS of 117 days.Conclusions: Anti‐BCMA CAR T cell treatment is safe and highly active in R/R multiple myeloma.Keywords
Funding Information
- National Natural Science Foundation of China (81873452, 81670152, 81600120)
This publication has 40 references indexed in Scilit:
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastomaScience Translational Medicine, 2015
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysisBlood Cancer Journal, 2014
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Current strategies for treatment of relapsed/refractory multiple myelomaExpert Review of Hematology, 2014
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia, 2013
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple MyelomaClinical Cancer Research, 2013
- Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working GroupLeukemia, 2012
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011